What's hot

View all perspectives
What's Hot

JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay

Watch video →

RheumNow Rheumatology Roundup: Drs. Kavanaugh and Cush

Rheumatology Roundup! Drs. Cush and Kavanaugh convene for their annual impromptu review of some of the best and more interesting abstracts presented at ACR 2021.    

Watch video →

TNF Inhibitor Panel Discussion: ACR21 Annual Meeting

RheumNow TNFi faculty convened to discuss several TNFi-related abstracts presented at ACR 21. Panelists: Drs. Aurelie Najm, Janet Pope, David Liew, Eric Dein and Swetha Alexander. 

Watch video →

Spondyloarthritis Panel Discussion: ACR21 Meeting

Panelists: Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood. Abstracts discussed include #0562, #1919, #0907, #0364 and #0919

Watch video →

Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay

Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.

Watch video →

Diagnosing (Bad) VEXAS: The Experts Speak Drs. Beck and Ferrada

Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting.

Watch video →

Pediatric Psoriatic Arthritis: Dr. Eric Ruderman

Dr. Ruderman discusses abstracts #1424 presented at the ACR21 annual meeting.

Watch video →

Urine Proteome Advances: What Do They Mean? Dr. Michelle Petri

Dr. Petri reviews abstracts #1422 and #1936, presented at the ACR21 annual meeting.

Watch video →

ACR21 Day 3 Recap: Polypharmacy, New Lupus Drugs, VEXAS, Safety Data

Blurb: Drs. Jack Cush and the RheumNow Faculty Drs. Akhil Sood, Antoni Chan, Olga Petryna and Eric Dein, discuss highlights from Day 3 (Monday) at the ACR21 annual meeting. Abstracts include #1367, #1044, #1444, #1083 and more.

Watch video →

Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles

Dr. Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.

Watch video →

Predictors of TNF Response with Drs. Pope, Dein and Liew

Drs. Janet Pope, David Liew and Eric Dein discuss TNF data presented at the ACR21 annual meeting, including abstracts #1251, #1442, #1448.

Watch video →

Caring for the Older Patient with Rheumatic Disease: Drs. Makris, Yung and Dao

Drs. Kathryn Dao, Una Makris and Raymond Yung discuss the field of geriatric rheumatology and caring for the older patient with rheumatic disease.

Watch video →

Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares

  Drs. Jack Cush, Yuz Yusof, Bella Mehta, Olga Petryna and Rachel Tate review autoinflammatory data presented at the ACR21 annual meeting, including abstracts #1100, #1062, #1426, #0252, #0195, and #1083.

Watch video →

FDA Session Review: Dr. Arthur Kavanaugh

Dr. Kavanaugh discussed the FDA session presented at the ACR21 annual meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.

Watch video →

The Respiratory Tract and RA with Drs. Sparks, McDermott and Kronzer

Drs. Jeffrey Sparks, Greg McDermott and Vanessa Kronzer discuss work in the area of respiratory disease in RA, mucosal paradigm, RA-ILD, bronchiectasis, as well as their experience as virtual attendees at the ACR21 annual meeting.

Watch video →

Pulmonary Hypertension in Adult Onset Still's Disease: Dr. Jack Cush

Dr. Cush reviews poster #1100 presented at the ACR21 annual meeting.

Watch video →

Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri

Dr. Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the ACR21 annual meeting.

Watch video →

ACR21 Day 2 Recap: CV Risk, Tapering in SpA, Microbiome in PsA, Vit D

Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 (Sunday) at the ACR21 Virtual meeting.

Watch video →
      RT @Janetbirdope: No effect if ⤴️LDL in #Tocilizumab on #cardiovascular events vs other bDMARDs. Nice study from Cor

      Janet Pope Janetbirdope

      4 years ago
      No effect if ⤴️LDL in #Tocilizumab on #cardiovascular events vs other bDMARDs. Nice study from Corona. Ok why would we think that minor changes in lipids in RA & improved inflammation and ⤵️CRP would affect CV events? NNH is enormous & need yrs of f/u @RheumNow #ACR21 abst0268 https://t.co/cW65PmQ61u
      RT @doctorRBC: Wonderful review on HES vs. EGPA by Dr. Amy Klion
      ⭐️1st line tx still steroids
      ⭐️New ACR 2021 EG

      Robert B Chao, MD doctorRBC

      4 years ago
      Wonderful review on HES vs. EGPA by Dr. Amy Klion ⭐️1st line tx still steroids ⭐️New ACR 2021 EGPA guidelines ⭐️ANCA status can affect EGPA tx response ⭐️mepolizumab useful for EGPA and HES ⭐️ongoing trial for benralizumab (anti-IL-5R) #ACR21 @RheumNow https://t.co/Xr99nAx5BA
      RT @bella_mehta: ACR and KL grades for identifying OA @carla_scanzello #ACR21 @RheumNow and New research proposed KOA c

      Bella Mehta bella_mehta

      4 years ago
      ACR and KL grades for identifying OA @carla_scanzello #ACR21 @RheumNow and New research proposed KOA criteria - updates in OA https://t.co/74j3RrpbG8
      RT @drdavidliew: While angiographic change thankfully is uncommon in large vessel vasculitis patients

      it's 3x more like

      David Liew drdavidliew

      4 years ago
      While angiographic change thankfully is uncommon in large vessel vasculitis patients it's 3x more likely at a given site if there was been baseline PET/CT activity there. Important step in understanding LVV natural history! @KQuinnRheum @petercgrayson #ACR21 ABST0503 @RheumNow https://t.co/ROjLZyvEj4
      RT @drdavidliew: So you say LVV is a monophasic disease?

      Look at these wavy lines, that keep on going up and down over

      David Liew drdavidliew

      4 years ago
      So you say LVV is a monophasic disease? Look at these wavy lines, that keep on going up and down over time for both TAK and GCA - dynamic change. The ESR/CRP might get better, but something below there keeps on burning... @KQuinnRheum @petercgrayson #ACR21 ABST0504 @RheumNow https://t.co/sxTR16p6WJ
      RT @MeralElRamahiMD: #ACR21 Abst#0455
      ABT improves subclin arthritis in +ACPA pts w/ MRI signs of [teno]synovitis or ost

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      #ACR21 Abst#0455 ABT improves subclin arthritis in +ACPA pts w/ MRI signs of [teno]synovitis or osteitis per ARIAA study ➡️61% w/ improved MRI findings vs 31% PBO ➡️Arthritis developed in 4 on ABT vs 17 PBO Do you use ABT for early RA? #ACRBest @Rheumnow https://t.co/btfH9lb6TU https://t.co/qOGkxSogZF
      RT @bella_mehta: MAS in sJIA - retrospective multicenter study 147 pts- 2 peds clinics in Turkey.
      22% developed MAS medi

      Bella Mehta bella_mehta

      4 years ago
      MAS in sJIA - retrospective multicenter study 147 pts- 2 peds clinics in Turkey. 22% developed MAS median 5 month multiple attacks per pt - highest being 4 51% remined on the same biologic and resulted in improvement @RheumNow #ACR21 #ACRBest #abst0246
      RT @KDAO2011: Assisted reproductive tech for pts w/ rheum dz is safe for stable/quiescent dz #acr21 ⁦@ACRheum⁩ repr

      TheDaoIndex KDAO2011

      4 years ago
      Assisted reproductive tech for pts w/ rheum dz is safe for stable/quiescent dz #acr21 ⁦@ACRheum⁩ reproductive guideline ⁦@RheumNow⁩ https://t.co/312EuRSJrB
      Fautrel reports mixed response to JAK Inhib. in 8 refractory Adult (6) & juvenile (2)-Onset Still's Dz w/ dz Dz dura

      Dr. John Cush RheumNow

      4 years ago

      Fautrel reports mixed response to JAK Inhib. in 8 refractory Adult (6) & juvenile (2)-Onset Still's Dz w/ dz Dz duration 86 mos (7 Systemic, 1 Chr articular) w/ JAKi (Bari 4, Upa1, Tofa 2, Ruxo 2). There were no remissions, 50% had partial response @ 11 mos #ACR21 Abstr#0195 https://t.co/Ww8ONBrRqq

      RheumNow’s expanded coverage of the #ACR21 meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All conte

      Dr. John Cush RheumNow

      4 years ago
      RheumNow’s expanded coverage of the #ACR21 meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its Faculty.
      RT @LauraLewMad11: #ACR21 #pedsrheum
      With so much work ahead, what to tackle first?
      1⃣Gathering and organizing the t

      Dr. Laura Lewandowski LauraLewMad11

      4 years ago
      #ACR21 #pedsrheum With so much work ahead, what to tackle first? 1⃣Gathering and organizing the top 10 priorities in cSLE https://t.co/H3ASXAfM4m
      RT @_Castillo_Pedro: Rheum Radiology Bootcamp
      Rheum dz = increased risk of lung cancer
      Important note: Fleischner recs f

      Pedro Castillo _Castillo_Pedro

      4 years ago
      Rheum Radiology Bootcamp Rheum dz = increased risk of lung cancer Important note: Fleischner recs for incidental nodules do not apply to immunosuppressed patients. Stay on alert for malignancy. #ACR2021
      RT @_Castillo_Pedro: Consider baseline risk of lung cancer. Scleroderma and RA in particular at increased risk => low

      Pedro Castillo _Castillo_Pedro

      4 years ago
      Consider baseline risk of lung cancer. Scleroderma and RA in particular at increased risk => lower threshold for getting initial CT. For incidental nodule, consider rescreening at 6-12 months, then space out. #ACR2021
      RT @uptoTate: Brepocitinib (TYK2/JAK1i) superior to PBO in PsA at week 16, w/ improvements in refractory domains continu

      Dr. Rachel Tate uptoTate

      4 years ago
      Brepocitinib (TYK2/JAK1i) superior to PBO in PsA at week 16, w/ improvements in refractory domains continuing over 52 weeks. There were more AEs in the brepocitinib groups vs PBO over 16 weeks. Abs 0488 #ACR21 #RheumNow @RheumNow https://t.co/umk4REJwkS https://t.co/JYZVR3jyY5
      RT @uptoTate: BE AGILE: No new safety signals in AS pts treated with BKZ ( IL-17F/IL-17Ai) and remains efficacious as a

      Dr. Rachel Tate uptoTate

      4 years ago
      BE AGILE: No new safety signals in AS pts treated with BKZ ( IL-17F/IL-17Ai) and remains efficacious as a potential treatment in AS. Abs 0491 #ACR21 #RheumNow @RheumNow https://t.co/fGT8n5Hx9C https://t.co/rjPTla7JId

      Podcasts

      • Giant Cell Arteritis and Polymyalgia Rheumatic Wrapup: Drs. Calabrese, Liew, Conway and Mackie 00:20:18
      • Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao 00:20:26
      • The Expert Gout Panel with Drs. Neogi, Saag, Pillinger, Cush and O'Dell 00:35:26

      Catch up on Conference Podcasts

      ×